ID   21M18
AC   CVCL_A4BK
DR   Wikidata; Q105505888
RX   Patent=US9376497;
RX   PubMed=19664991;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8670.
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized demcizumab (OMP-21M18) therapeutic antibody.
CC   Monoclonal antibody isotype: Not specified.
CC   Monoclonal antibody target: UniProtKB; Q9NR61; Human DLL4.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
CA   Hybridoma
DT   Created: 12-01-21; Last updated: 02-05-24; Version: 6
//
RX   Patent=US9376497;
RA   Gurney A.L., Axelrod F.T., Hoey T., Satyal S.;
RT   "Compositions and methods for diagnosing and treating cancer.";
RL   Patent number US9376497, 28-Jun-2016.
//
RX   PubMed=19664991; DOI=10.1016/j.stem.2009.05.019;
RA   Hoey T., Yen W.-C., Axelrod F.T., Basi J., Donigian L., Dylla S.J.,
RA   Fitch-Bruhns M., Lazetic S., Park I.-K., Sato A., Satyal S.,
RA   Wang X.-H., Clarke M.F., Lewicki J., Gurney A.L.;
RT   "DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell
RT   frequency.";
RL   Cell Stem Cell 5:168-177(2009).
//